Dana R, Malech H L, Levy R
Laboratory of Infectious Diseases and Clinical Biochemistry Unit, Faculty of Health Sciences, Soroka Medical Center of Kupat Holim, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Biochem J. 1994 Jan 1;297 ( Pt 1)(Pt 1):217-23. doi: 10.1042/bj2970217.
Phospholipase A2 (PLA2) inhibitors suppressed simultaneously, in a dose-dependent manner, the activation of NADPH oxidase and the release of 3H-labelled arachidonic acid ([3H]AA) stimulated by either phorbol 12-myristate 13-acetate (PMA) or opsonized zymosan (OZ) in human neutrophils. In spite of total inhibition of superoxide production in the presence of the PLA2 inhibitors, 10 microM bromophenacyl bromide (BPB) or 20 microM quinacrine, a maximal phosphorylation of p47 and translocation of p47 and p67 to the neutrophil membranes induced by PMA or OZ was observed. Addition of 10 microM free AA, which by itself did not stimulate superoxide generation, restored oxidase activity in neutrophils treated with PLA2 inhibitors. These findings indicate that phosphorylation and translocation of the cytosolic factors to the membranes are not sufficient for generating superoxide; a functional PLA2 is also needed to stimulate the oxidase activity. The inhibition of PLA2 activity did not prevent the phosphorylation of p47, suggesting that the location of PLA2 is downstream of and does not activate protein kinase C.
磷脂酶A2(PLA2)抑制剂以剂量依赖的方式同时抑制了人中性粒细胞中由佛波醇12 - 肉豆蔻酸酯13 - 乙酸酯(PMA)或调理酵母聚糖(OZ)刺激的NADPH氧化酶的激活和3H标记的花生四烯酸([3H]AA)的释放。尽管在PLA2抑制剂存在下超氧化物生成被完全抑制,但观察到10微摩尔溴苯甲酰溴(BPB)或20微摩尔奎纳克林存在时,PMA或OZ诱导的p47最大磷酸化以及p47和p67向中性粒细胞膜的转位。添加10微摩尔游离AA本身并不刺激超氧化物生成,但能恢复用PLA2抑制剂处理的中性粒细胞中的氧化酶活性。这些发现表明,胞质因子向膜的磷酸化和转位不足以产生超氧化物;还需要功能性PLA2来刺激氧化酶活性。PLA2活性的抑制并未阻止p47的磷酸化,这表明PLA2的作用位点在蛋白激酶C的下游且不激活蛋白激酶C。